RecruitingNCT05775432

Prognosis of Heart Transplanted Patients With Heart Failure

Prognosis of Heart Transplanted Patients With Heart Failure (RE-START): a National Multi-center, Retrospective-prospective, Cohort Study


Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Enrollment

1,000 participants

Start Date

Apr 23, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Heart transplantation is the most effective treatment for end-stage heart failure, advanced cardiomyopathy, and complex congenital heart disease with severe heart failure or hypoxia. Several clinical studies have shown significant differences in the prognosis of heart transplantation patients with different etiologies, and post-transplantation complications are an important factor affecting patient survival, and there is still a lack of overall prognostic stratification and extensive clinical studies on risk factors after heart transplantation. Therefore, this study is intended to include patients who underwent heart transplantation for different etiologies of heart failure, collect clinical data and biological samples from patients, and use various techniques to deeply interpret the risk factors affecting the prognosis of heart transplantation patients and construct a prognostic prediction model to provide specific and individualized treatment ideas and theoretical basis for improving the survival rate of patients after heart transplantation.


Eligibility

Min Age: 3 YearsMax Age: 80 Years

Inclusion Criteria2

  • Patients with end-stage heart failure presented to our hospital who are evaluated by clinicians and ethically approved for heart transplantation
  • Individuals whose hearts are donated

Exclusion Criteria1

  • Patients refuse to sign informed consent form

Locations(1)

First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05775432


Related Trials